Stablix takes targeted protein degradation’s tactics in reverse

Stablix is the among the first companies founded to extend the logic of protein degradation to a different enzymatic process — in this case, stabilizing proteins via deubiquitination.

The company emerged from stealth Thursday with a $63 million series A round led by founding investor Versant Ventures, with participation from NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities. ...